Related Experiment Video
Updated: May 10, 2025
09:32
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
14.4K
PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer
Xiaopeng Zhuang1, Huiting Li2, Zhijie You1
1Department of Pathology, The Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
Annals of Diagnostic Pathology
|April 24, 2025
Summary
PD-L1 (SP263) expression in prostate cancer correlates with aggressive features like high Gleason Group and advanced stage. This suggests PD-L1 may help stratify risk and guide combined therapies involving p53 inhibitors and PD-1/PD-L1 antibodies.
Area of Science:
- Oncology
- Immunology
- Pathology
Background:
- Research on PD-L1 (SP263) expression in prostate cancer (PC) is limited.
- Understanding PD-L1 expression is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the expression of PD-L1 (SP263) in prostate cancer.
- To explore the correlations between PD-L1 expression and clinicopathological parameters in PC.
Main Methods:
- Analyzed 265 PC samples using immunohistochemistry for PD-L1 (SP263), p53, ERG, PTEN, HER-2, and Ki-67.
- Performed next-generation sequencing for TP53 and BRCA1/2 in 17 patients.
- Assessed associations between PD-L1 status and clinicopathological parameters using statistical analyses.
Main Results:
- PD-L1 positivity (10.2%) was associated with advanced age, high Gleason Group, T3/4 stage, positive surgical margin, aberrant p53/TP53, and elevated Ki-67.
- No significant associations were found with serum PSA, N/M stage, PTEN, ERG, BRCA1/2, or survival outcomes.
Conclusions:
- PD-L1 (SP263) expression is linked to pathologically aggressive features in PC.
- PD-L1 may serve as a biomarker for risk stratification in prostate cancer.
- Combined targeting of PD-L1/p53 pathways could be a potential therapeutic strategy for PC.
